Is AI Creating the Drugs of the Future?

For the first time, a team of scientists has used artificial intelligence to create a useful drug.

The drug, which is meant to treat obsessive compulsive disorder, is now being tested in clinical trials.

What is so remarkable about this drug is the process through which it was invented. Using artificial intelligence, researchers took only one year to develop a medication ready for a clinical trial. Traditional drug research methods usually take five years to churn out a workable product. And that is just for the research phase; the next step is to collect clinical data in human trials, which can take time as well.

Clinical TrialsAt the moment, researchers are calling the new drug DSP-1181. A catchier moniker might be given once it passes the human trial phase. In the meantime, clinical data will be gathered to show how effective the medication is in treating OCD. Scientists are hopeful that the drug will be a success.


  1. A UK-based AI company called Exscientia and a Japanese pharmaceutical company called Sumitomo Dainippon Pharma collaborated to create the drug.
  2. This is the first time artificial intelligence has been used to create a new drug.
  3. The main benefit of using AI in drug development is the speed at which AI can identify useful chemical compounds.

Article Source:
Image Source:

#ClinicalTrial #ClinicalData #ArtificialIntelligence

P.S. Trying to keep up with what’s new in Clinical Trials? Catch the latest article summaries delivered straight to your inbox. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria for EUROLogin2020


Read more
Nubilaria ACTide @ SCOPE Virtual 2021

SCOPE – Summit for Clinical Ops Executives

Read more
Nubilaria Christmas wishes 2020

Merry Christmas and Happy new Year

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems